Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance study in ulcerative colitis
2016-004676-22Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in autoimmune colitis (3 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical remission per Adapted Mayo score at Week 52. Started Apr 2018; status: active.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-004676-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004676-22.